For example, the inflammatory and fibrogenic pathophysiological conditions were largely suppressed with the treatment of chymase-specific inhibitor TY-51469 in animal-model experiments, resembling nonalcoholic steatohepatitis [28], inflammatory bowel disease [29], and intraperitoneal adhesions [30]. Here, CMA1 is linked to metabolic dysfunction-associated steatohepatitis.